Biotech Investor Stock News Alert; BioSante (NASDAQ: BPAX) Trading its Way Back to $3.00

Point Roberts, WA, LINCOLNSHIRE, Ill –September 9, 2011,– Investorideas.com, a leader in sector stock research for independent investors , issues a trading alert for specialty biotech/pharma stock, BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) for  the week of September 9th.

The stock has bounced back as high as $2.82 in today’s trading, and was up 9.9% yesterday at $2.89.

In recent commentary on Motley Fool,3 Biotechs Ready to Move, the author noted, "Despite the future risks, though, there's no doubt BioSante will rise on positive efficacy data. With a market cap under $300 million, there are very little sales baked into the price."



News Excerpt: Pharma News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at Three September Healthcare Conferences
“LINCOLNSHIRE, Ill. - September 1, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that BioSante will present at three healthcare conferences in September. The three presentations are as follows: on Wednesday, September 7, 2011 at 9:45 am EDT at the Stifel Nicolaus Healthcare Conference in Boston; on Monday, September 12, 2011 at 1:35 pm EDT at the Rodman & Renshaw Healthcare Conference in New York; and on September 27, 2011 at 2:00 pm EDT at the JMP Securities Healthcare Conference in New York.

BioSante will provide a company overview at each conference, as well as an update on the LibiGel® (testosterone gel) Phase III clinical development program and planned new drug application (NDA) submission.

A live audio webcast of remarks by Phillip Donenberg, senior vice president & CFO of BioSante, at the Stifel Nicolaus Conference may be accessed at http://www.veracast.com/webcasts/stifel/healthcare 2011/ 07104418.cfm:  the webcast will be archived for 30 days. A live audio webcast of remarks by Stephen M. Simes, president & CEO of BioSante, at the Rodman Conference may be accessed at http://www.wsw.com/webcast/ rrshq20/bpax: the webcast will be archived for 90 days. A live audio webcast of Mr. Simes’ remarks at the JMP Conference can be accessed at http://www.wsw.com/webcast/ jmp14/bpa/: the webcast will be archived for 90 days.”
Full News at: http://www.investorideas.com/CO/BPAX/news/2011/09011.asp

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology.  BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA).  BioSante’s first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante’s licensee.  BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials.  Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology.  Additional information is available online at: www.biosantepharma.com.

To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante’s plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions  and other statements identified by words such as “will,” “continue,” “could,”  “believe,” “intends,” “continue,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning, derivations of such words or the use of future dates.  Forward-looking statements by their nature address matters that are, to different degrees, uncertain.  Uncertainties and risks may cause BioSante’s actual results to be materially different than those expressed in or implied by BioSante’s forward-looking statements.  For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante’s licensees or sublicensees; the success of clinical testing; and BioSante’s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante’s actual results are described in BioSante’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q.  All forward-looking statements in this news release speak only as of the date of this news release.  BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact BioSante:
For info about BioSante Pharmaceuticals, Inc

For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com

For Media:
McKinney/Chicago
Alan Zachary
(312) 506-5220
azachary@mckinneychicago.com

BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com

Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp

Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp

About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.

Disclaimer: The following news/content is paid for as part of the  BPAX showcase program  (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp  
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  

Source: Investorideas.com, BioSante, Investorideas.com
Contact Investorideas.com

800 665 0411 cvanzant@investorideas.com

Wednesday’s Biotech Stocks Trading; LGND, CTIC, AVII, DNDN, OTC: AEMD

Point Roberts, WA- September 08, 2011- Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for September 07, 2011.

Aethlon Medical, Inc. (OTC:AEMD) closed lower by 3.03% to $0.0640 on volume of 164K shares and is now trading higher in the morning session, up OVER 15%. The Company recently reported it has entered into an agreement with the Sarcoma Oncology Center to study the ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients.

Top gaining stocks in the sector yesterday included Ligand Pharmaceuticals Inc. (NASDAQ:LGND) traded higher by 1.92 (13.68%) and closed at new multi-year high of $15.95. Yesterday’s rally was followed by sharp fall of 10% in the past one week. So far this year, the stock has jumped over 79%.

Cell Therapeutics, Inc. (NASDAQ:CTIC) continued to move higher and rose another 8.85% to $1.23. The stock has been showing strong support at $1 mark and has jumped about 20% in the past one month. The stock has 52-week range of $1-$3.33.

AVI BioPharma, Inc. (NASDAQ:AVII) shares also climbed 0.08 (7.41%) to $1.16 bouncing back from its recent fall of about 8% in the past one week. The stock had made its new 52-week low of $1.02 earlier during this week. The stock has 52-week range of $1.02-$2.74.

Dendreon Corporation   (NASDAQ:DNDN) gained 0.80 (7.40%) to $11.61 on high volume. The company’s management will host a conference call on Thursday, September 8, 2011 at 4:30 p.m. ET to provide a structural and business update on the company.


Biotech Medical Company Snapshot for Aethlon Medical (OTCBB: AEMD)

Visit the AEMD showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
or www.aethlonmedical.com
The Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.

Contacts:  
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sectors. Sectors we cover include; water stocks, gold and mining stocks, China stocks, oil and gas stocks, renewable energy stocks, coal stocks, tech stocks, biotech stocks, defense stocks, nanotech, agriculture and gaming.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook   http://www.facebook.com/Investorideas

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC (OTC BB: AEMD) Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock) Effective March 15, 2011      
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
www.InvestorIdeas.com/About/Disclaimer.asp 

800-665-0411 -
Source - Investorideas.com

Investorideas.com Newswire - Pharma News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at Three September Healthcare Conferences

Investorideas.com Newswire - Pharma News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at Three September Healthcare Conferences

Pharma News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at Three September Healthcare Conferences

LINCOLNSHIRE, Ill. - September 1, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that BioSante will present at three healthcare conferences in September. The three presentations are as follows: on Wednesday, September 7, 2011 at 9:45 am EDT at the Stifel Nicolaus Healthcare Conference in Boston; on Monday, September 12, 2011 at 1:35 pm EDT at the Rodman & Renshaw Healthcare Conference in New York; and on September 27, 2011 at 2:00 pm EDT at the JMP Securities Healthcare Conference in New York.

BioSante will provide a company overview at each conference, as well as an update on the LibiGel® (testosterone gel) Phase III clinical development program and planned new drug application (NDA) submission.

A live audio webcast of remarks by Phillip Donenberg, senior vice president & CFO of BioSante, at the Stifel Nicolaus Conference may be accessed at http://www.veracast.com/webcasts/stifel/healthcare 2011/ 07104418.cfm: the webcast will be archived for 30 days. A live audio webcast of remarks by Stephen M. Simes, president & CEO of BioSante, at the Rodman Conference may be accessed at http://www.wsw.com/webcast/ rrshq20/bpax: the webcast will be archived for 90 days. A live audio webcast of Mr. Simes’ remarks at the JMP Conference can be accessed at http://www.wsw.com/webcast/ jmp14/bpa/: the webcast will be archived for 90 days.

About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.

Contact:
BioSante Pharmaceuticals
For Investors:The Trout Group LLCTricia Swanson(646) 378-2953tswanson@troutgroup.com

or
For Media:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316azachary@mckinneychicago.com

BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com

Visit this company: www.biosantepharma.com


Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp

Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp

About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.

Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Source: Investorideas.com, BioSante, Investorideas.com

800 665 0411 cvanzant@investorideas.com

More Info:

Published at www.Investorideas.com - Global research by sectors

If you have any questions regarding information in this press release please contact the company listed in the press release.

Connect with Investorideas.com: http://www.twitter.com/Investorideas
Publish Your News - Send a release: http://www.investorideas.com/News-Upload/

Disclaimer: The following news is paid for and /or published as information only for our readers.Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Biopharmaceutical Company Talon Therapeutics Inc (OTC: TLON) Leads Gainers

Monday’s OTC Percentage Gainers: OTC: TLON, OTC: EXTO, OTC: PBSOQ, OTC: SOLU

Biopharmaceutical Company Talon Therapeutics Inc (OTC: TLON) Leads Gainers

POINT ROBERTS, (Aug 30, 2011) - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the OTCBB for Aug 29.

Talon Therapeutics Inc (OTC: TLON) shares jumped 0.210 (28.77%) to $0.94 with more than 250K shares traded hands after the company has reached agreement with the U. S. Food and Drug Administration (FDA) regarding a special protocol assessment (SPA) for its planned Phase 3 study of Marqibo(R) (vincristine sulfate liposomes injection) in adults with newly diagnosed Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL).

EXIT ONLY INC (OTC:EXTO) gained 0.0023 (28.75%) to $0.0103 on over 43.38 million shares traded hands after it announced that its recently acquired Bayport Corporation, at a directors' meeting on August 26, 2011, approved an amendment to its Articles of Incorporation reducing the number of Authorized Shares from 3,000,000,000 down to 850,000,000. This change is effective immediately and will be reflecting in the Nevada SOS database shortly.
Point Blank Solutions, Inc. (OTC: PBSOQ) added 0.230 (47.92%) to $0.710. Point Blank Solutions Inc announced that it has entered into a stalking horse Asset Purchase Agreement (APA) with an affiliate of The Gores Group, a well known and established private equity firm.
SOLUTIONS GROUP INC (OTC:SOLU) climbed 0.0027 (81.82%) to $0.0060 after Southwest Airlines awarded a contract to Southwest Solutions Group to build and install a high density storage system for their Payroll department. Southwest Airlines' recent growth created a need for additional space for the Payroll department's file storage.

Investorideas.com Free Investor Tools;
Learn More about Investorideas.com showcase stocks
http://www.investorideas.com/Showcase/


Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp


Join Investor Ideas – Become a Member
Research renewable energy stocks, gold stocks, water stocks, oil and gas and more with the largest stock directories online for investors
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only 13 stock directories in leading sectors including renewable energy, water and energy stocks.
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/



About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas


Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894


Source – Investorideas.com

800-665-0411 – cvanzant@investorideas.com



More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory Biotech Companies - become a biotech showcase stock on www.investorideas.com and www.biotechindustrystocks.com for as little as $1000 month !

Biotech Stock Alert: Aethlon (OTCBB: AEMD) Makes Headlines with Cancer Studies

Biotech Stock Alert: Aethlon (OTCBB: AEMD) Makes Headlines with Cancer Studies

Visit this company: www.aethlonmedical.com

SAN DIEGO – August 25, 2011 (Investorideas.com newswire) - Investorideas.com, a leader in investor research including biotech stocks issues the following news alert for Aethlon Medical, Inc. (OTCBB: AEMD)

Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, reports it has entered into an agreement with the Sarcoma Oncology Center to study the ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients. Exosomes released by cancer have recently emerged as a novel therapeutic target in cancer care, as they have been implicated in cancer survival, growth, and metastasis. Researchers have also identified that cancer-released exosomes may assist tumors in evading the response of the immune system. At present, there is no therapeutic drug candidate to inhibit the deleterious roles of cancer-released exosomes. The Aethlon Hemopurifier® is a first-in-class medical device with broad-spectrum capabilities against viral pathogens, including HIV and Hepatitis C virus. The device has also demonstrated the ability to capture cancer-released exosomes from cell culture and human ascites fluids. Click here (Aethlon Exosome Presentation) to learn more about Aethlon's novel therapeutic strategy to address cancer.

(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

"The opportunity to test the ability of our Hemopurifier® to remove exosomes from the blood of cancer patients represents an important step in our effort to improve cancer care," stated Aethlon Chairman and CEO, Jim Joyce. "Additionally, we will have the privilege of working with Dr. Sant Chawla, a leading authority in the sarcoma oncology field and his team at the Sarcoma Oncology Center."

The study will be conducted in collaboration with The Sarcoma Oncology Center (www.sarcomaoncology.com) based in Santa Monica, California. The Sarcoma Oncology Center is one of the most sought after research centers for the clinical testing of new therapeutic candidates against sarcomas and other forms of cancer. Click on (ASCO 2011) to view the Center's clinical presentations at the 2011 American Society of Oncology conference. The lead investigator of the study is Dr. Sant P. Chawla (About Dr. Chawla). Dr. Chawla noted, "This clinical histological study is a critical validation step in Aethlon's Hemopurifier® strategy for cancer that we hope will set the stage for planned therapeutic trials in cancer patients. The concept of 'subtractive therapy', eliminating a major mechanism of tumor progression and resistance to drugs, represents a potential breakout solution that needs to be tested in the clinic." The initial study will quantitate and capture exosomes ex-vivo, from blood samples of patients with advanced cancers. The study will evaluate 25 patients, five patients with metastatic cancer of the following types; non-small cell lung cancer, prostate cancer, melanoma, head and neck cancer, and sarcoma. Successful study outcomes would provide a basis for advancing human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies.

About Aethlon Medical

The Aethlon Medical mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Aethlon ADAPT™ system is an expansive technology platform that converges affinity drug agents and plasma membrane technology to create therapeutic filtration devices that selectively target the removal of harmful particles from the entire circulatory system. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a device with broad-spectrum capabilities against viral pathogens and immunosuppressive cancer exosomes. In human studies, Hemopurifier® therapy has provided significant viral load reductions in HIV and hepatitis C virus infected individuals without the administration of antiviral drugs. We are now focused on advancing our Hemopurifier® as an adjunct strategy to improve the benefit of established infectious disease and cancer treatment regimens. Based on studies conducted by government and non-government research organizations, the Hemopurifier® is also a leading broad-spectrum treatment candidate to address bioterror and pandemic threats. For more information, please visit www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability to demonstrate ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients, future therapeutic trials in cancer patients, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier's® ability to capture exosomes and the impact it may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

Contacts:

James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com

Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com

AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page

Disclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) is a paid advertising client ($one thousand five hundred per month, $five thousand per month in 144 stock)

More Info:

Published at www.Investorideas.com - Global research by sectors

If you have any questions regarding information in this press release please contact the company listed in the press release.

Connect with Investorideas.com




Publish Your News - Send a release

Disclaimer: The following news is paid for and /or published as information only for our readers (175 top energy news).
Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.

Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894




More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory Biotech Companies - become a biotech showcase stock on www.investorideas.com and www.biotechindustrystocks.com for as little as $1000 month !

Investorideas.com - Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) Announces Sarcoma, Lung Cancer, Prostate Cancer, Metastatic Melanoma, and Head and Neck Cancer Studies

Investorideas.com - Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) Announces Sarcoma, Lung Cancer, Prostate Cancer, Metastatic Melanoma, and Head and Neck Cancer Studies

Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) Announces Sarcoma, Lung Cancer, Prostate Cancer, Metastatic Melanoma, and Head and Neck Cancer Studies

SAN DIEGO – August 24, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has entered into an agreement with the Sarcoma Oncology Center to study the ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients. Exosomes released by cancer have recently emerged as a novel therapeutic target in cancer care, as they have been implicated in cancer survival, growth, and metastasis. Researchers have also identified that cancer-released exosomes may assist tumors in evading the response of the immune system. At present, there is no therapeutic drug candidate to inhibit the deleterious roles of cancer-released exosomes. The Aethlon Hemopurifier® is a first-in-class medical device with broad-spectrum capabilities against viral pathogens, including HIV and Hepatitis C virus. The device has also demonstrated the ability to capture cancer-released exosomes from cell culture and human ascites fluids. Click here (Aethlon Exosome Presentation) to learn more about Aethlon's novel therapeutic strategy to address cancer.

(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

The opportunity to test the ability of our Hemopurifier® to remove exosomes from the blood of cancer patients represents an important step in our effort to improve cancer care," stated Aethlon Chairman and CEO, Jim Joyce. "Additionally, we will have the privilege of working with Dr. Sant Chawla, a leading authority in the sarcoma oncology field and his team at the Sarcoma Oncology Center."

The study will be conducted in collaboration with The Sarcoma Oncology Center (www.sarcomaoncology.com) based in Santa Monica, California. The Sarcoma Oncology Center is one of the most sought after research centers for the clinical testing of new therapeutic candidates against sarcomas and other forms of cancer. Click on (ASCO 2011) to view the Center's clinical presentations at the 2011 American Society of Oncology conference. The lead investigator of the study is Dr. Sant P. Chawla (About Dr. Chawla). Dr. Chawla noted, "This clinical histological study is a critical validation step in Aethlon's Hemopurifier® strategy for cancer that we hope will set the stage for planned therapeutic trials in cancer patients. The concept of 'subtractive therapy', eliminating a major mechanism of tumor progression and resistance to drugs, represents a potential breakout solution that needs to be tested in the clinic." The initial study will quantitate and capture exosomes ex-vivo, from blood samples of patients with advanced cancers. The study will evaluate 25 patients, five patients with metastatic cancer of the following types; non-small cell lung cancer, prostate cancer, melanoma, head and neck cancer, and sarcoma. Successful study outcomes would provide a basis for advancing human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies.

About Aethlon Medical
The Aethlon Medical mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Aethlon ADAPT™ system is an expansive technology platform that converges affinity drug agents and plasma membrane technology to create therapeutic filtration devices that selectively target the removal of harmful particles from the entire circulatory system. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a device with broad-spectrum capabilities against viral pathogens and immunosuppressive cancer exosomes. In human studies, Hemopurifier® therapy has provided significant viral load reductions in HIV and hepatitis C virus infected individuals without the administration of antiviral drugs. We are now focused on advancing our Hemopurifier® as an adjunct strategy to improve the benefit of established infectious disease and cancer treatment regimens. Based on studies conducted by government and non-government research organizations, the Hemopurifier® is also a leading broad-spectrum treatment candidate to address bioterror and pandemic threats. For more information, please visit www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability to demonstrate ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients, future therapeutic trials in cancer patients, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier's® ability to capture exosomes and the impact it may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

Contacts:
James A. JoyceChairman, CEO858.459.7800 x301jj@aethlonmedical.com

Jody CainSenior Vice President, Lippert/Heilshorn & Associates310.691.7100jcain@lhai.com

Jim FrakesChief Financial Officer858.459.7800 x300jfrakes@aethlonmedical.com

John P. SalvadorDirector, Communications & Investor Relations858.459.7800 x307jps@aethlonmedical.com

AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com

Visit this company: www.aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page
Disclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) is a paid advertising client ($one thousand five hundred per month, $five thousand per month in 144 stock)

Published at www.Investorideas.com - Global research by sectors

If you have any questions regarding information in this press release please contact the company listed in the press release.

Connect with Investorideas.com: http://www.twitter.com/Investorideas
Publish Your News - Send a release: http://www.investorideas.com/News-Upload/

Disclaimer: The following news is paid for and /or published as information only for our readers (175 top energy news).
Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Investorideas.com Newswire - Investor FAQs and Facts for BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX)

Investorideas.com Newswire - Investor FAQs and Facts for BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX)


Investor FAQs and Facts for BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX)


POINT ROBERTS, August 24, 2001 - www.InvestorIdeas.com, a global investor research portal for independent investors features an investor FAQ and Fact Sheet for specialty pharmaceutical company, BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX).

BioSante’s (NASDAQ: BPAX) stock has built a significant retail investor following as well as over 40% institutional ownership and has had extensive media coverage as its key product, LibiGel®, gets closer to market as the first FDA-approved drug for female sexual dysfunction. The following FAQs and Facts can serve as an important stage of due diligence for investors and media following the company’s progress.


BioSante FAQs (Frequently asked Questions)

1) In the correct market environment cash is king. How long will your cash last?
A: BioSante is well funded and has the financial resources to continue our corporate strategy well into 2013, with a current burn rate averaging $4 Million per month which will decrease to approximately $3 million per month in 2012. As of August 2, 2011 we had about $79 million in cash.

2) What is the timeline for LibiGel clinical development?
A: LibiGel is in three pivotal Phase III clinical studies at this time. The first two trials are set to be completed in September 2011 with top-line efficacy data reported in the fourth quarter 2011. Top-line data from the third study, a safety study, will be reported in the third quarter 2012. A new drug application (NDA) is targeted to be submitted in 2012 and a potential FDA approval could come in mid-2013.

3) Other companies have tried to develop products for the treatment of female sexual dysfunction. Why is BioSante the only company active in Phase III clinical development for this indication today?
A: As stated before we believe the market for female sexual dysfunction is significant and we would welcome other companies to develop product for this market. Having said that, today LibiGel is the only product in Phase III clinical development in the world. Previous companies have failed in their development either because their efficacy data were not adequate or they did not prove the safety of their products to FDA’s satisfaction. We believe the LibiGel Phase III clinical program will show both the efficacy and the safety of LibiGel in the treatment of female sexual dysfunction, specifically hypoactive sexual desire disorder, a significant unmet medical need among women.

4) How big is the market for FSD?
A: The current market for testosterone and estrogen products is over $2.5 billion dollars in the U.S. alone, with estimates for female sexual dysfunction (FSD) potentially adding more than $2.0 billion. Unfortunately a full 13 years after Viagra was approved for men’s sexual health there still is no FDA-approved product for the treatment of women’s sexual health.

5) How will LibiGel be marketed?
A: According to IMS and primary research, in 2010, over four million “off label” testosterone prescriptions were written for women in the U.S. According to survey data, clinicians indicated that they would prefer to prescribe an FDA approved product that has been clinically tested and proven to be safe and effective for the treatment of HSDD, and they would switch over 90% of their patients using testosterone to LibiGel®. In addition, the physicians indicated the number of women using testosterone for HSDD would more than double given an FDA approved product. Our objective is to license LibiGel to a larger company to market it once approved.

6) Does BioSante have a pipeline beyond LibiGel?
A: Yes, BioSante has a long list of products in clinical development as well as pending FDA approval. Clearly, LibiGel represents our biggest and best near-term opportunity. In addition, our male testosterone product, Bio-T-Gel™ has an NDA pending and has been licensed to Teva for marketing in the U.S. In addition we have a portfolio of cancer vaccine currently in 15 Phase I and Phase II studies. Importantly, these studies are funded by others and therefore BioSante has no cost, but significant potential upside. Investors should visit our website, www.biosantepharma.com, to review our full product portfolio as well as review our public filings for the most information about our company.

BioSante Facts
What investors need to know about BioSante

Investment Highlights

• Financial resources to continue corporate strategy well into 2013
• Late stage pharmaceutical product portfolio with significant growth potential
• LibiGel in three ongoing Phase III safety and efficacy clinical studies
• Elestrin is FDA approved and marketed in the U.S.
• Bio-T-Gel™ has NDA pending
• Proprietary cancer vaccines in Phase II clinical trials
• Focused growth strategy
• Management’s proven ability to gain FDA approval, implement plans and increase stockholder value

Financial Highlights

• At August 2, 2011, BioSante had approximately $79M in cash
• Monthly burn rate of approximately $4.0M

Key Products

LibiGel® — In development under an SPA for treatment of female sexual dysfunction. Three Phase III safety and efficacy clinical studies are ongoing.

ElestrinTM — FDA approved transdermal gel for treatment of hot flashes; currently
marketed in the U.S. by Azur Pharma.

Bio-T-GelTM — An NDA has been filed byTeva USA for the treatment of hypogonadism
in men.

The Pill-PlusTM — Triple component contraceptive in Phase II clinical development
combining oral contraceptive and androgen. Licensed to and being developed
by Pantarhei Bioscience for oral uses.

Cancer Vaccines — A portfolio of cancer vaccines in Phase II clinical trials for various
cancer types, conducted at Johns Hopkins Cancer Center.

Read the August 2011 Fact Sheet in Full
http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf


About BioSante Pharmaceuticals, Inc.
http://www.biosantepharma.com/

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante’s first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology.

Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante’s plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as “will,” “continue,” “could,” “believe,” “intends,” “continue,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante’s actual results to be materially different than those expressed in or implied by BioSante’s forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante’s licensees or sublicensees; the success of clinical testing; and BioSante’s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante’s actual results are described in BioSante’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information, please contact:
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953; tswanson@troutgroup.com

For Media:
McKinney/Chicago
Alan Zachary
312-506-5220;
azachary@mckinneychicago.com

BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com

Request news, updates and trading alerts on BPAX http://www.investorideas.com/Resources/Newsletter.asp

Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer: The following investor idea and featured is a not a recommendation, but a profile of one of many publicly traded biotech and pharma stocks for investors to research. Disclosure: BPAX is a featured showcase stock and compensates Investorideas.com (six thousand five hundred for three months advertising) our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894


Contact Investorideas.com
800-665-0411 – dawn@investorideas.com or cvanzant@investorideas.com

Source – Investorideas.com